The "Prostate Care Market (2025 Edition): Analysis By Treatment Type (Medications, Surgical Treatments, Minimally Invasive Therapies, and Radiation Therapy), By Disease Type, By End-User: Market Insights and Forecast (2021-2031)" report has been added to ResearchAndMarkets.com's offering.

The Global Prostate Care market showcased growth at a CAGR of 7.62% during 2021-2024. The market was valued at USD 39.06 Billion in 2024 which is expected to reach USD 69.91 Billion in 2031.

This report provides a complete analysis for the historical period of 2021-2024, the estimates of 2025 and the forecast period of 2026-2031.

The Global Prostate Care Market is operating within a dynamic and evolving healthcare ecosystem, driven by demographic shifts, technological innovations, and a growing awareness of men's health issues. The market primarily focuses on the prevention, diagnosis, and treatment of prostate-related conditions such as Benign Prostatic Hyperplasia (BPH), Prostate Cancer, and Prostatitis, which are increasingly prevalent, particularly among the aging male population. With prostate cancer being one of the most common cancers among men worldwide, the demand for advanced screening tools, targeted therapies, and personalized treatment regimens continues to rise.

One of the key operational strengths of the market lies in the integration of multidisciplinary care approaches and technological advancements. Diagnostic innovations such as Prostate-Specific Antigen (PSA) tests, MRI fusion biopsies, and genomic testing have significantly improved early detection and risk stratification. Simultaneously, therapeutic advancements - ranging from robot-assisted laparoscopic prostatectomy and minimally invasive procedures like UroLift and Rezum therapy, to cutting-edge radiation therapies like brachytherapy and intensity-modulated radiation therapy (IMRT) - are shaping a more patient-centered and outcome-driven market. Pharmaceutical advancements, including androgen deprivation therapy (ADT), chemotherapy, and immunotherapies, are offering more targeted and tolerable treatment options.

From an operational perspective, hospitals, urology centers, and specialty clinics form the backbone of service delivery. These healthcare providers are increasingly adopting value-based care models, supported by real-world evidence and electronic health records, which enhance patient tracking, follow-ups, and clinical outcomes. In parallel, home care settings are emerging as a viable alternative for chronic management and post-surgical recovery, fueled by telehealth adoption and patient preference for convenience and privacy.

The market is growing at a robust pace due to a combination of macroeconomic and societal factors. The global increase in life expectancy, rising incidence of lifestyle-related health issues, and greater emphasis on preventive healthcare are expanding the target patient base. Moreover, healthcare reforms, especially in developing regions, are improving access to diagnostic services and prostate treatments. Countries like the U.S., Germany, China, and Japan are leading the charge with significant investments in healthcare infrastructure, screening programs, and public awareness campaigns.

Commercially, the market is witnessing heightened competition among leading players such as Medtronic plc, Johnson & Johnson, Boston Scientific Corporation, and Abbott Laboratories, all of whom are focusing on product innovation, clinical trials, mergers and acquisitions, and strategic partnerships to strengthen their market positions. Digital health tools, including mobile health apps, AI-driven diagnostic platforms, and remote monitoring systems, are also being integrated into prostate care strategies, signaling a move toward precision medicine and digital therapeutics.

Scope of the Report

• The report analyses the Prostate Care Market by Value (USD Billion).
• The report analyses the Prostate Care Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Brazil, Germany, United Kingdom, France, Italy, China, Japan, and India).
• The report presents the analysis of Prostate Care Market for the historical period of 2021-2024, the estimated year 2025 and the forecast period of 2026-2031.
• The report analyses the Prostate Care Market by Treatment Type (Medications, Surgical Treatments, Minimally Invasive Therapies, and Radiation Therapy).
• The report analyses the Prostate Care Market by Disease Type (Benign Prostatic Hyperplasia (BPH), Prostate Cancer, and Prostatitis).
• The report analyses the Prostate Care Market by End-User (Hospitals & Clinics, Specialty Urology Centers, and Home Care Settings).
• The key insights of the report have been presented through the frameworks of SWOT. Also, the attractiveness of the market has been presented by region, by Treatment Type, by Disease Type, & by End-User.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development.

Analyst Recommendations

• Invest in Early Detection and Screening Innovations
• Expand Access Through Telehealth and Remote Monitoring

Competitive Positioning

• Companies' Product Positioning
• Market Share Analysis of Prostate Care Market
• Company Profiles
• Abbott Laboratories
• AstraZeneca plc
• Bayer AG
• Boston Scientific Corporation
• Eli Lilly and Company
• Johnson & Johnson
• Medtronic plc

For more information about this report visit https://www.researchandmarkets.com/r/9pbukq

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250721498244/en/